Jongwon Im

This paper develops a tumor-targeting engineered bacterium that improves therapeutic efficacy and safety in cancer treatment.

This paper engineers probiotic bacteria to target granulomas and reduce mycobacterial infection in vitro and in vivo.

The paper introduces NanoPro, a nanovector therapy platform using probiotically-released tumor-binding tags to target antigenically indistinct tumors, demonstrating in vitro efficacy with high transduction rates.

This paper develops a bacterial platform that combines enzyme/prodrug chemotherapy and immunotherapy to enhance antitumor responses with improved safety in a murine tumor model.

This study engineers probiotic E. coli to deliver neoantigen peptides, enhancing T cell immunity and reducing tumor growth in mice.

This study examines the effects of chronic and acute fentanyl exposure on midbrain organoids, finding that chronic treatment arrests neuronal development and alters synaptic pathways.

This paper develops a programmable probiotic encapsulation system using synthetic biology to enhance therapeutic delivery in mice by controlling bacterial immunogenicity and survivability.